The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1
about
Emerging pharmacotherapies for neurodevelopmental disordersEffect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trialThe genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disordersTumor microenvironment and neurofibromatosis type I: connecting the GAPsThe PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.Dysregulation and restoration of translational homeostasis in fragile X syndromeRASopathies: unraveling mechanisms with animal modelsNetworking in autism: leveraging genetic, biomarker and model system findings in the search for new treatmentsProtein prenylation and synaptic plasticity: implications for Alzheimer's diseaseTreatment of neurodevelopmental disorders in adulthoodFrom neurodevelopment to neurodegeneration: the interaction of neurofibromin and valosin-containing protein/p97 in regulation of dendritic spine formationPotential for treatment of severe autism in tuberous sclerosis complexActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsNeurofibromin Loss of Function Drives Excessive Grooming in DrosophilaReview of targeted treatments in fragile X syndromePrioritizing the development of mouse models for childhood brain disordersRas and Rap signaling in synaptic plasticity and mental disorders.Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculatureReduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.Teaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches.mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeStatins, bone, and neurofibromatosis type 1Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1.Curing epilepsy: progress and future directionsThe genetics of autism: key issues, recent findings, and clinical implications.Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neuronsDefective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.Abnormal circadian oscillation of hippocampal MAPK activity and power spectrums in NF1 mutant mice.Insights into synaptic function from mouse models of human cognitive disorders.Rapamycin for treating Tuberous sclerosis and Autism spectrum disordersThe receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning.Neurofibromin regulates corticostriatal inhibitory networks during working memory performanceSimvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.Neurofibromatosis type 1: modeling CNS dysfunction.Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteinsImpaired Pten expression in human malignant peripheral nerve sheath tumours.Skeletal muscle and motor deficits in Neurofibromatosis Type 1.
P2860
Q24619170-BECD918A-CF2F-4BE3-A8EE-F6B52B7AD896Q24647676-B89E3BD3-E2D6-427C-8A90-A0B69F4A2CC7Q24650845-F12CE758-4B2F-47EC-BC4C-2903AD464AC1Q24654681-BFAE9357-2CF6-471C-A162-03C8C65BF195Q26766054-15576E21-C775-43D5-840F-EA0DCD059C47Q26782616-8A89810C-E65C-46A5-B159-36EBFF944950Q26800379-2C8A94AD-684F-49DB-B5D9-3F442BB7E273Q26850307-5F317355-91C4-417E-A524-A9659F25894EQ26858942-389CDD6E-8A98-4C25-B1CC-474AB96B6F1CQ27000307-D9F3AFBD-18EB-4828-A782-F8A66EB0F4FEQ27015865-CD06D12E-15A8-451A-91E6-46FB45F1811DQ27021739-BDF7EBD6-8ED0-4DA1-B386-75CB5B78CC9EQ27027458-FF8A2F6E-F5C3-4880-8C16-84E87677ABC8Q27347271-12259771-BCAB-4CD4-B990-3DF03D435B8CQ28077180-38690A0F-3076-4509-86F7-3BAD1EB07314Q30366940-CF5FC610-0676-4BE3-AF5C-B1846E170954Q30431817-8DD1AAB0-9A41-4850-A515-D47D186130ACQ30440266-8865498C-15C8-4F0A-B5E0-C325994D0858Q30497049-DA6AC184-50EF-4520-88A3-253FC59CB331Q30531079-D872D7CB-1E69-445B-9A3B-0FD0477176A7Q30537599-7828D664-9016-406A-A7DF-A7DE830A3ED1Q30670424-13AD343A-1CBC-4C72-BB75-1A81C892E7CBQ30821694-A8841CE5-676F-4E63-8EF5-BFF8CFFD4BC8Q33356748-277C08A3-55E8-40BA-BC6B-D34FB84CE301Q33589650-00A1152F-1185-4C89-B69E-76FB6EB3D098Q33655266-58C94A60-BA18-4E3D-B1AC-A8FBAA418CC9Q33739608-087F93A6-841B-4FB5-8B5C-DC8ACE9DB390Q33743618-6543B2F9-CA2C-4813-A92B-E11837310F7FQ33831164-C7FCBACB-26EE-4D16-BF49-FF0DA99C480CQ33869070-5D700526-8EFE-43AA-80DF-E147FC2EE2F4Q33964940-750C4D9D-1143-410C-A18E-27CB4D1F3305Q34024856-99222244-1461-4F46-8695-AC59E3F777A3Q34031191-5F67C188-3EFF-404C-BADC-CFAE69AF71D9Q34059456-8ADA8C88-5997-4AAB-9229-64BA9D075589Q34081527-DE26921A-968D-4FE6-A83E-20072F2F30CAQ34094097-EBD7AF60-6A35-4A9B-B2F5-6DDADDEE97ECQ34305314-1EF4932E-A1B7-46DD-9016-DDBA9E5E1049Q34432977-3F29E646-9D07-4B6A-B03D-CC144082F2E3Q34471826-AAB5BC7B-A1F3-4226-9347-04384C662856Q34478793-4ECC20B3-7B38-471B-86ED-AD9FCAD96F5C
P2860
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1
description
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2005
@ast
im November 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2005/11/08)
@sk
vědecký článek publikovaný v roce 2005
@cs
wetenschappelijk artikel (gepubliceerd op 2005/11/08)
@nl
наукова стаття, опублікована в листопаді 2005
@uk
مقالة علمية (نشرت في 8-11-2005)
@ar
name
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@ast
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@en
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@nl
type
label
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@ast
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@en
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@nl
prefLabel
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@ast
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@en
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@nl
P2093
P3181
P1433
P1476
The HMG-CoA reductase inhibito ...... el of neurofibromatosis type 1
@en
P2093
Alcino J. Silva
Paul W. Frankland
Robert A. M. Brown
Steven A. Kushner
Weidong Li
P304
P3181
P356
10.1016/J.CUB.2005.09.043
P407
P577
2005-11-08T00:00:00Z